OncoGenex Pharmaceuticals Inc. (NASDAQ:ACHV) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a note issued to investors on Friday.

Shares of OncoGenex Pharmaceuticals (NASDAQ:ACHV) traded down 0.57% during mid-day trading on Friday, hitting $3.49. 19,320 shares of the stock were exchanged. The firm’s market cap is $9.55 million. The stock’s 50 day moving average is $2.14 and its 200 day moving average is $0.87. OncoGenex Pharmaceuticals has a 12 month low of $2.45 and a 12 month high of $10.18.

OncoGenex Pharmaceuticals (NASDAQ:ACHV) last posted its quarterly earnings results on Monday, July 31st. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter.

ILLEGAL ACTIVITY NOTICE: This piece was originally posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/09/03/oncogenex-pharmaceuticals-inc-achv-cut-to-sell-at-valuengine.html.

OncoGenex Pharmaceuticals Company Profile

Achieve Life Sciences, Inc, formerly OncoGenex Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company’s segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for OncoGenex Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoGenex Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.